section name header

Pronunciation

mycophenolate mofetil: mye-koe-FEE-noe-late MOE-fe-til

mycophenolic acid: mye-koe-FEE-noe-lik

Classifications

Therapeutic Classification: Immunosuppressant agents

Indications

REMS


Mycophenolate mofetil

Mycophenolic acid

Action

  • Inhibits the enzyme inosine monophosphate dehydrogenase, which is involved in purine synthesis. This inhibition results in suppression of T- and B-lymphocyte proliferation.
Therapeutic effects:

Pharmacokinetics

Absorption: Following oral and IV administration, mycophenolate mofetil is rapidly hydrolyzed to mycophenolic acid (MPA), the active metabolite. Absorption of enteric-coated mycophenolic acid (Myfortic) is delayed compared with mycophenolate mofetil (CellCept).

Distribution: Cross the placenta and enter breast milk.

Protein Binding: MPA: 97%.

Metabolism/Excretion: MPA is extensively metabolized; <1% excreted unchanged in urine. Some enterohepatic recirculation of MPA occurs.

Half-Life: MPA: 8–18 hr.

Time/Action Profile

(blood levels of MPA)

ROUTEONSETPEAKDURATION
mycophenolate mofetil-POrapid0.25–1.25 hrN/A
mycophenolic acidrapid1.5–2.75 hrN/A





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Mycophenolate Mofetil

Renal Impairment

Mycophenolic Acid

Availability

(Generic available)

Mycophenolate Mofetil

Mycophenolic Acid

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

mycophenolate mofetil: CellCept,

mycophenolic acid: Myfortic